Daniel R. van Langenberg
About
In The Last Decade
Daniel R. van Langenberg
76 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 104
- Genetics 1.0k
- Epidemiology 828
- Surgery 286
- Gastroenterology 270
- Immunology 162
Countries citing papers authored by Daniel R. van Langenberg
This map shows the geographic impact of Daniel R. van Langenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. van Langenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. van Langenberg more than expected).
Fields of papers citing papers by Daniel R. van Langenberg
This network shows the impact of papers produced by Daniel R. van Langenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. van Langenberg. The network helps show where Daniel R. van Langenberg may publish in the future.
Co-authorship network of co-authors of Daniel R. van Langenberg
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R. van Langenberg. A scholar is included among the top collaborators of Daniel R. van Langenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R. van Langenberg. Daniel R. van Langenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 4 | |
| 3 | 24 | |
| 4 | 22 | |
| 5 | 19 | |
| 6 | 0 | |
| 7 | 20 | |
| 8 | 4 | |
| 9 | 5 | |
| 10 | 5 | |
| 11 | Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study | 2 |
| 12 | 30 | |
| 13 | 1 | |
| 14 | 49 | |
| 15 | 1 | |
| 16 | Apparent efficacy and safety of low dose naltrexone in Australian patients with active Crohn's disease | 1 |
| 17 | 69 | |
| 18 | 57 | |
| 19 | Factors in Crohn’s disease important in maintaining the integrity of muscle : the forgotten cousin of bone | 1 |
| 20 | 30 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.